Antibiotics for travelers: What's good and what's not

Current Infectious Disease Reports

Volumn 6, Issue 1, 2004, Pages 13-21

  Suh, Kathryn N ^a   Keystone, Jay S ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; DOXYCYCLINE; FANSIDAR; FLUCONAZOLE; GATIFLOXACIN; HALOFANTRINE; LEVOFLOXACIN; MACROLIDE; MEFLOQUINE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PHENYTOIN; PLACEBO; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; SUNSCREEN; TETRACYCLINE DERIVATIVE; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL DISCOMFORT; ANOREXIA; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; CONSULTATION; DEVELOPED COUNTRY; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG USE; ENVIRONMENT; ESOPHAGUS INJURY; FLUSHING; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INJURY; LEPTOSPIROSIS; LYME DISEASE; MALARIA; MEDICAL SPECIALIST; NAUSEA; NONHUMAN; PARASITOSIS; PARESTHESIA; PHOTOTOXICITY; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SELF MEDICATION; SIDE EFFECT; TASTE DISORDER; TENDON RUPTURE; TRAVEL; TRAVELLER DIARRHEA; VAGINA CANDIDIASIS; VERTIGO; VOMITING;

EID: 5144235177     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0019-0     Document Type: Review

References (53)

1. Spira AM: Preparing the traveller. Lancet 2003, 361:1368-1381.
2. Steffen R, Rickenbach M, Wilhelm U, et al.: Health problems after travel to developing countries. J Infect Dis 1987, 156:84-91.
3. Hill DR: Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 2000, 7:259-266.
4. Dallimore J, Cooke RJ, Forbes K: Morbidity on youth expeditions to developing countries. Wilderness Environ Med 2002, 13:1-4.
5. Hargarten SW, Baker TD, Guptill K: Overseas fatalities of United States citizen travelers: an analysis of deaths related to international travel. Ann Emerg Med 1991, 20:622-626.
6. McPherson DW, Guerillot F, Streiner DL, et al.: Death and dying abroad: the Canadian experience. J Travel Med 2000, 7:227-233.
7. Parola P, Raoult D: Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis 2001, 32:897-928.
8. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, et al.: Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 1991, 337:1140-1143.
9. Overbosch D, Schilthuis H, Bienzle U et al.: Atovaquoneproguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001, 33:1015-1021.
10. Kofoed K, Petersen E: The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. J Travel Med 2003, 10:150-154.
11. Committee to Advise on Tropical Medicine and Travel (CAT-MAT): Canadian recommendations for the prevention and treatment of malaria among international travelers 2000. Can Commum Dis Rep 2000, 26(Suppl 2):1-42.
12. Schalgenhauf P: Standby emergency treatment by travelers. In Travelers' Malaria. Edited by Schlag P. Hamilton, Ontario: BC Decker; 2001:446-462.
13. Sanders EJ, Rigau-Perez JG, Smits HL, et al.: Increase of leptospirosis in dengue-negative patients after a hurricane in Puerto Rico in 1996. Am J Trop Med Hyg 1999, 61:399-404.
14. Update: leptospirosis and unexplained febrile illness among athletes participating in triathlons - Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep 1998, 47:673-676.
15. Farr RW: Leptospirosis. Clin Infect Dis 1995, 21:1-8.
16. JevonTR, Knudson MP, Smith PA, et al.: A point-source epidemic of leptospirosis: description of cases, cause, and prevention. Postgrad Med 1986, 80:121-122, 127-129.
17. Outbreak of leptospirosis among white-water rafters - Costa Rica, 1996. MMWR Morb Mortal Wkly Rep 1997, 46: 577-579.
18. Haake DA, Dundoo M, Cader R, et al.: Leptospirosis, water sports, and chemoprophylaxis. Clin Infect Dis 2002, 34: e40-e43.
19. Takafuji ET, Kirkpatrick JW, Miller PN, et al.: An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984, 310:497-500.
20. Sehgal SC, Sugunan AP, Murhekar MV, et al.: Randomized controlled trial of doxycycline prophylaxis against leptospirosis in an endemic area. Int J Anticmirob Agents 2000, 13:249-255.
21. Guidugli F, Castro AA, Atallah AN: Antibiotics for preventing leptospirosis. Cochrane Database Syst Rev 2000, 4:CD001305.
22. Gonsalez CR, Casseb J, Monteiro FG, et al.: Use of doxycycline for leptospirosis after high-risk exposure in Sao Paulo, Brazil. Rev Inst Med Top Sao Paulo 1998, 40:59-61.
23. McClain JBL, Ballou WR, Harrison SM, Steinweg DL: Doxycycline therapy for leptospirosis. Ann Intern Med 1984, 100:696-698.
24. Nadelman RB, Nowakowski J, Forseter G, et al.: The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996, 100:502-508.
25. Nadelman RB, Nowakowski J, Fish D, et al.: Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001, 345:79-84.
26. Shapiro ED, Gerber MA, Holabird NB, et al.: A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992, 327:1769-1773.
27. DuPont HL., Ericsson CD: Prevention and treatment of traveler's diarrhea. N Engl J Med 1993, 328:1821-1827.
28. Matilla L: Clinical features and duration of traveler's diarrhea in relation to its etiology. Clin Infect Dis 1994, 19:728-734.
29. Andsell VE, Ericsson CD: Prevention and empiric treatment of traveler's diarrhea. Med Clin North Am 1999, 83:945-973.
30. Ericsson CD: Traveler's diarrhea. Int J Antimicrob Agents 2003, 21:116-124.
31. Sanders JW, Isenbarger DW, Walz SE, et al.: An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg 2002, 67:533-538.
32. Hoge CW, Gambel JM, Srijan A, et al.: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Inject Dis 1998, 26:341-345.
33. DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW: Five versus three days of ofloxacin therapy for travelers' diarrhea: a placebo controlled study. Antimicrob Agents Chemother 1992, 36: 87-91.
34. Petruccelli BP, Murphy GX, Sanchez JL, et al.: Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Inject Dis 1992, 165:557-560.
35. Ericsson CD, DuPont HL, Mathewson JJ: Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of travelers' diarrhea. J Travel Med 1997, 4:3-7.
36. Thomson MA, Booth IW: Treatment of travellers' diarrhea. Pharmacoeconomics 1996, 9:382-391.
37. Tellier R, Keystone JS: Prevention of travelers' diarrhea. Infect Dis Clin North Am 1992, 6:333-354.
38. van der Linden PD, Sturkenboom MC, Herings RM, et al.: Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003, 163:1801-1807.
39. Tupasi TE: Quinolones in the developing world: state of the art. Drugs 1999, 58:55-59.
40. Kuschner R, Trofa AF, Thomas RJ, et al.: Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995, 21:536-541.
41. Gomi H, Jiang ZD, Adachi JA, et al. : In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001, 45:212-216.
42. Giardiasis surveillance, United States - 1992-1997. MMWR Morb Mortal Wkly Rep 2000, 49:1-24.
43. Gardner TB, Hill DR: Treatment of giardiasis. Clin Microbiol Rev 2001, 14:114-128.
44. Miller KD, Lobel HO, Satriale RF, et al.: Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986, 35:451-458.
45. Ashkenazi S, Amir J, Waisman Y, et al.: A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr 1993, 123:817-821.
46. Memon IA, Billoo AG, Memon HI: Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. South Med J 1997, 90:1204-1207.
47. Watson DA: Pretravel health advice for asplenic individuals. J Travel Med 2003, 10:117-121.
48. Waghorn DJ: Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001, 54:214-218.
49. Mileno MD: Preparation of immunocompromised travelers. In Travel Medicine. Edited by Keystone JS, Kozarsky PE, Freedman DO, et al. Philadelphia: Mosby; 2004:249-256.
50. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2002, 51:1-52.
51. Wilson ME, Fordham von Reyn F, Finberg HV. Infections in HIV infected travelers: risk and prevention. Ann Intern Med 1991, 114:582-592.
52. Simons FM, Cobelens FG, Danner SA: Common health problems in HIV-infected travelers to the (sub)tropics. J Travel Med 1999, 6:71-75.
53. Castelli F, Patroni A: The human immunodeficiency virus-infected traveler. Clin Infect Dis 2000, 31: 1403-1408.